Successful Management of Hyperbilirubinemia with Snehapana and Virechana: A Case Report

Authors

  • Dr. Sudhanva Koodur Assistant Professor, Department of Panchakarma, KTG Ayurveda Medical College, Hegganahalli, Bangalore, Karnataka.

DOI:

https://doi.org/10.47070/ijraps.v9i7.211

Keywords:

Hyperbilirubinemia, Snehapana, Virechana, Indukanta Ghrita.

Abstract

Background: Hyperbilirubinemia reflects impaired bilirubin metabolism, usually due to hepatic dysfunction or bile flow obstruction. Ayurveda considers such conditions to be Pitta-dominant disorders affecting Yakrit and Ranjaka Pitta. Classical Panchakarma therapies such as Snehapana and Virechana are indicated for detoxification and Pitta elimination.

Case: A 35-year-old male presented with mild jaundice, fatigue, dark-coloured urine, and a history of asthmatic bronchitis. Laboratory evaluation revealed elevated total (2.5 mg/dL), direct (1.2 mg/dL), and indirect (1.3 mg/dL) bilirubin levels. The patient underwent Snehapana with Indukanta Ghrita followed by Virechana with Trivrit Avaleha.

Intervention and Outcome: Samyak Snehana signs were achieved on the fourth day. Virechana produced Madhyama Shuddhi with 13 Vegas. Post-therapy bilirubin values returned to normal limits (total 0.3 mg/dL, direct 0.1 mg/dL, indirect 0.2 mg/dL). The patient reported significant improvement in jaundice, breathing difficulty, and fatigue.

Conclusion: This case demonstrates the potential efficacy of Ayurvedic Panchakarma -specifically Snehapana and Virechana-in managing hyper-bilirubinemia and improving liver function. Further controlled studies are warranted.

Downloads

Download data is not yet available.

Published

2025-10-25

Issue

Section

Articles

How to Cite

1.
Successful Management of Hyperbilirubinemia with Snehapana and Virechana: A Case Report. IJRAPS [Internet]. 2025 Oct. 25 [cited 2025 Dec. 6];9(7):1-3. Available from: https://www.ijraps.in/index.php/ijraps/article/view/211

Similar Articles

You may also start an advanced similarity search for this article.